+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report by Type (Amyloid-related Markers, Tau-related Markers, Neurodegeneration), by Technology (Immunoassays), by End-use, by Region, and Segment Forecasts, 2025-2033- Product Image
Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report by Type (Amyloid-related Markers, Tau-related Markers, Neurodegeneration), by Technology (Immunoassays), by End-use, by Region, and Segment Forecasts, 2025-2033- Product Image
New

Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report by Type (Amyloid-related Markers, Tau-related Markers, Neurodegeneration), by Technology (Immunoassays), by End-use, by Region, and Segment Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • August 2025
  • Region: Global
  • Grand View Research
  • ID: 6168173
Description Jump to:
The global blood-based biomarker for Alzheimer’s disease diagnostics market size was estimated at USD 139.69 million in 2024 and is expected to reach USD 429.31 million by 2033, growing at a CAGR of 15.07% from 2025 to 2033. A pivotal catalyst was the U.S. FDA’s May 16, 2025, marketing clearance of Fujirebio’s Lumipulse G pTau217/β-amyloid 1-42 plasma ratio-the first Alzheimer’s blood test cleared to aid diagnosis-quickly followed by Labcorp’s nationwide launch on Aug 18, 2025.

These steps lower adoption friction (regulatory clarity, distribution) and are expected to accelerate payer uptake and clinician ordering, intensifying the growth curve for blood tests relative to imaging and CSF. Guidance presented at AAIC 2025 and published by the Alzheimer’s Association states that blood-based biomarker (BBM) tests with ≥90% sensitivity and ≥75-90% specificity can triage-and at higher performance, substitute for-amyloid PET or CSF testing in appropriate patients. p-tau217-containing panels consistently outperform earlier generations (Aβ42/40 or p-tau181 alone) for detecting amyloid and tau pathology. Real-world product data are converging: Quest’s 2025 AD-Detect™ reported >90% sensitivity and specificity for Alzheimer’s pathology in AAN-presented analyses, while clinical summaries highlight ~92% positive and ~97% negative agreement for the FDA-cleared Lumipulse test. As clinicians gain confidence in rule-in/rule-out accuracy, ordering shifts from specialty memory clinics to broader frontline settings, expanding test volumes and normalizing BBMs as the first diagnostic step.

Technology maturation and clinical validation add momentum. Blood assays targeting phosphorylated tau (especially p-tau217) have received Breakthrough Device designations and now full FDA clearance, reflecting strong clinical validity and utility.

Academic-industry consortia (e.g., UW-Madison, Johns Hopkins, Lund) supplied pivotal data underpinning the cleared IVD. Published reviews conclude that blood-based biomarker tests (BBMTs) bring value by reducing invasiveness and enabling earlier triage-crucial when disease-modifying therapies are most effective in prodromal/mild stages. Market traction examples include reference-lab launches and hospital adoption for memory-clinic pathways, where a positive p-tau217/Aβ ratio can expedite PET scheduling while a negative result can avoid costly scans. As platforms scale, expect menu expansion (neurofilament light, GFAP, Aβ42/40), reflex algorithms, and bundled panels, improving sensitivity/specificity and supporting longitudinal monitoring-opening recurring-test revenue beyond one-time diagnosis.

Global Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the global blood-based biomarker for Alzheimer’s disease diagnostics market report based on type, technology, end-use, and region:

Type Outlook (Revenue, USD Million, 2021-2033)

  • Amyloid-related markers
  • Tau-related markers
  • Neurodegeneration
  • Others

Technology Outlook (Revenue, USD Million, 2021-2033)

  • Immunoassays
  • Mass spectrometry-based assays
  • Next-generation platforms
  • Others

End-use Outlook (Revenue, USD Million, 2021-2033)

  • Clinical laboratories & hospital labs
  • Pharma & biotech
  • Academic & research institutes
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type Segment
1.1.1.2. Technology Segment
1.1.1.3. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Executive Summary
2.1. Market Snapshot
2.2. Type and Technology Snapshot
2.3. End Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Regulatory approvals and clinical validation
3.4.2. Rising demand for early and non-invasive diagnosis
3.4.3. Integration with disease-modifying therapies (DMTS)
3.5. Market Restraint Analysis
3.5.1. Reimbursement and coverage challenges
3.5.2. Standardization and validation barriers
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Type Estimates & Trend Analysis
4.1. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Type Movement Analysis
4.2. Amyloid-related markers
4.2.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.3. Tau-related markers
4.3.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.4. Neurodegeneration
4.4.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.5. Others
4.5.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Technology Estimates & Trend Analysis
5.1. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Technology Movement Analysis
5.2. Immunoassays
5.2.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.3. Mass spectrometry-based assays
5.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.4. Next-generation platforms
5.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Others
5.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: End Use Estimates & Trend Analysis
6.1. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: End Use Movement Analysis
6.2. Clinical laboratories & hospital labs
6.2.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.3. Pharma & biotech
6.3.1. Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.4. Academic & research institutes
6.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Others
6.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Regional Business Analysis
7.1. Regional Market Snapshot
7.2. North America
7.2.1. North America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Estimates and Forecast, 2021-2033 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.2.2.2. Key Country Dynamics
7.2.2.3. Regulatory Framework
7.2.2.4. Reimbursement Scenario
7.2.2.5. Competitive Scenario
7.2.3. Canada
7.2.3.1. Canada Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.2.3.2. Key Country Dynamics
7.2.3.3. Regulatory Framework
7.2.3.4. Reimbursement Scenario
7.2.3.5. Competitive Scenario
7.2.4. Mexico
7.2.4.1. Mexico Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.2.4.2. Key Country Dynamics
7.2.4.3. Regulatory Framework
7.2.4.4. Reimbursement Scenario
7.2.4.5. Competitive Scenario
7.3. Europe
7.3.1. Europe Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.3.2. UK
7.3.2.1. UK Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.3.2.2. Key Country Dynamics
7.3.2.3. Regulatory Framework
7.3.2.4. Reimbursement Scenario
7.3.2.5. Competitive Scenario
7.3.3. Germany
7.3.3.1. Germany Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.3.3.2. Key Country Dynamics
7.3.3.3. Regulatory Framework
7.3.3.4. Reimbursement Scenario
7.3.3.5. Competitive Scenario
7.3.4. Spain
7.3.4.1. Spain Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.3.4.2. Key Country Dynamics
7.3.4.3. Regulatory Framework
7.3.4.4. Reimbursement Scenario
7.3.4.5. Competitive Scenario
7.3.5. France
7.3.5.1. France Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.3.5.2. Key Country Dynamics
7.3.5.3. Regulatory Framework
7.3.5.4. Reimbursement Scenario
7.3.5.5. Competitive Scenario
7.3.6. Italy
7.3.6.1. Italy Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.3.6.2. Key Country Dynamics
7.3.6.3. Regulatory Framework
7.3.6.4. Reimbursement Scenario
7.3.6.5. Competitive Scenario
7.3.7. Denmark
7.3.7.1. Denmark Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.3.7.2. Key Country Dynamics
7.3.7.3. Regulatory Framework
7.3.7.4. Reimbursement Scenario
7.3.7.5. Competitive Scenario
7.3.8. Sweden
7.3.8.1. Sweden Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.3.8.2. Key Country Dynamics
7.3.8.3. Regulatory Framework
7.3.8.4. Reimbursement Scenario
7.3.8.5. Competitive Scenario
7.3.9. Norway
7.3.9.1. Norway Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.3.9.2. Key Country Dynamics
7.3.9.3. Regulatory Framework
7.3.9.4. Reimbursement Scenario
7.3.9.5. Competitive Scenario
7.4. Asia-Pacific
7.4.1. Asia-Pacific Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.4.2.2. Key Country Dynamics
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Scenario
7.4.2.5. Competitive Scenario
7.4.3. China
7.4.3.1. China Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.4.3.2. Key Country Dynamics
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Scenario
7.4.3.5. Competitive Scenario
7.4.4. India
7.4.4.1. India Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.4.4.2. Key Country Dynamics
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Scenario
7.4.4.5. Competitive Scenario
7.4.5. South Korea
7.4.5.1. South Korea Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.4.5.2. Key Country Dynamics
7.4.5.3. Regulatory Framework
7.4.5.4. Reimbursement Scenario
7.4.5.5. Competitive Scenario
7.4.6. Thailand
7.4.6.1. Thailand Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.4.6.2. Key Country Dynamics
7.4.6.3. Regulatory Framework
7.4.6.4. Reimbursement Scenario
7.4.6.5. Competitive Scenario
7.4.7. Australia
7.4.7.1. Australia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.4.7.2. Key Country Dynamics
7.4.7.3. Regulatory Framework
7.4.7.4. Reimbursement Scenario
7.4.7.5. Competitive Scenario
7.5. Latin America
7.5.1. Latin America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.5.2.2. Key Country Dynamics
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Scenario
7.5.2.5. Competitive Scenario
7.5.3. Argentina
7.5.3.1. Argentina Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.5.3.2. Key Country Dynamics
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Scenario
7.5.3.5. Competitive Scenario
7.6. MEA
7.6.1. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.6.2.2. Key Country Dynamics
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Scenario
7.6.2.5. Competitive Scenario
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.6.3.2. Key Country Dynamics
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Scenario
7.6.3.5. Competitive Scenario
7.6.4. UAE
7.6.4.1. UAE Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.6.4.2. Key Country Dynamics
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Scenario
7.6.4.5. Competitive Scenario
7.6.5. Kuwait
7.6.5.1. Kuwait Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021-2033 (USD Million)
7.6.5.2. Key Country Dynamics
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Scenario
7.6.5.5. Competitive Scenario
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. New Production Launch
8.2.2. Patnerships
8.2.3. Acquisition
8.2.4. Collaboration
8.2.5. Funding
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
8.5.1. F. Hoffmann-La Roche Ltd
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Quanterix
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Fujirebio
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. C2N Diagnostics
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Labcorp
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Quest Diagnostics Incorporated
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Siemens Healthineers
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Lilly USA, LLC
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Abbott
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. ALZpath
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Region, 2021-2033 (USD Million)
Table 4 Global Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 5 Global Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 6 Global Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 7 North America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Country, 2021-2033 (USD Million)
Table 8 North America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 9 North America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 10 North America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 11 U.S. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 12 U.S. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 13 U.S. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 14 Canada Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 15 Canada Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 16 Canada Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 17 Mexico Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 18 Mexico Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 19 Mexico Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 20 Europe Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Country, 2021-2033 (USD Million)
Table 21 Europe Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 22 Europe Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 23 Europe Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 24 UK Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 25 UK Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 26 UK Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 27 Germany Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 28 Germany Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 29 Germany Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 30 France Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 31 France Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 32 France Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 33 Italy Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 34 Italy Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 35 Italy Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 36 Spain Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 37 Spain Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 38 Spain Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 39 Sweden Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 40 Sweden Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 41 Sweden Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 42 Norway Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 43 Norway Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 44 Norway Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 45 Denmark Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 46 Denmark Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 47 Denmark Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 48 Asia-Pacific Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Country, 2021-2033 (USD Million)
Table 49 Asia-Pacific Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 50 Asia-Pacific Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 51 Asia-Pacific Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 52 Japan Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 53 Japan Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 54 Japan Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 55 China Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 56 China Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 57 China Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 58 India Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 59 India Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 60 India Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 61 Australia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 62 Australia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 63 Australia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 64 Thailand Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 65 Thailand Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 66 Thailand Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 67 South Korea Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 68 South Korea Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 69 South Korea Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 70 Latin America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Country, 2021-2033 (USD Million)
Table 71 Latin America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 72 Latin America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 73 Latin America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 74 Brazil Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 75 Brazil Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 76 Brazil Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 77 Argentina Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 78 Argentina Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 79 Argentina Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 80 MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Country, 2021-2033 (USD Million)
Table 81 MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 82 MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 83 MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 84 South Africa Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 85 South Africa Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 86 South Africa Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 87 Saudi Arabia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 88 Saudi Arabia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 89 Saudi Arabia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 90 UAE Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 91 UAE Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 92 UAE Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 93 Kuwait Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Type, 2021-2033 (USD Million)
Table 94 Kuwait Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 95 Kuwait Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, by End Use, 32021 - 2033 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Market summary
Figure 4 Market segmentation & scope
Figure 5 Market size and growth prospects
Figure 6 Global Blood-based biomarker for Alzheimer’s disease diagnostics market- Key market driver analysis
Figure 7 Global Blood-based biomarker for Alzheimer’s disease diagnostics market - Key market restraint analysis
Figure 8 Penetration & growth prospect mapping
Figure 9 Global Blood-based biomarker for Alzheimer’s disease diagnostics market - Porter’s analysis
Figure 10 Global Blood-based biomarker for Alzheimer’s disease diagnostics market - PESTEL analysis
Figure 11 Global Blood-based biomarker for Alzheimer’s disease diagnostics market Type outlook key takeaways
Figure 12 Global Blood-based biomarker for Alzheimer’s disease diagnostics market: Type movement analysis
Figure 13 Amyloid-related markers market estimates, 2021-2033 (USD Million)
Figure 14 Tau-related markers market estimates, 2021-2033 (USD Million)
Figure 15 Neurodegeneration market estimates, 2021-2033 (USD Million)
Figure 16 Others market estimates, 2021-2033 (USD Million)
Figure 17 Global Blood-based biomarker for Alzheimer’s disease diagnostics market technology outlook key takeaways
Figure 18 Global Blood-based biomarker for Alzheimer’s disease diagnostics market: technology movement analysis
Figure 19 Immunoassays market estimates, 2021-2033 (USD Million)
Figure 20 Mass spectrometry-based assays market estimates, 2021-2033 (USD Million)
Figure 21 Next-generation platforms market estimates, 2021-2033 (USD Million)
Figure 22 Others market estimates, 2021-2033 (USD Million)
Figure 23 Global Blood-based biomarker for Alzheimer’s disease diagnostics market end use outlook key takeaways
Figure 24 Global Blood-based biomarker for Alzheimer’s disease diagnostics market: end use movement analysis
Figure 25 Clinical laboratories & hospital labs market estimates, 2021-2033 (USD Million)
Figure 26 Pharma & biotech market estimates, 2021-2033 (USD Million)
Figure 27 Academic & research institutes market estimates, 2021-2033 (USD Million)
Figure 28 Others market estimates, 2021-2033 (USD Million)
Figure 29 Regional marketplace: Key takeaways
Figure 30 Global Blood-based Biomarker for Alzheimer’s Disease Diagnostics market: Regional movement analysis
Figure 31 North America Blood-based Biomarker for Alzheimer’s Disease Diagnostics market, 2021-2033 (USD Million)
Figure 32 U.S. Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 33 Canada Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 34 Mexico Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 35 Europe Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 36 UK Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 37 Germany Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 38 France Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 39 Spain Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 40 Italy Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 41 Denmark Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 42 Sweden Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 43 Norway Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 44 Asia-Pacific Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 45 Japan Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 46 China Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 47 India Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 48 South Korea Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 49 Australia Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 50 Thailand Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 51 Latin America Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 52 Brazil Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 53 Argentina Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 54 MEA Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 55 South Africa Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 56 Saudi Arabia Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 57 UAE Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 58 Kuwait Blood-based biomarker for Alzheimer’s disease diagnostics market, 2021-2033 (USD Million)
Figure 59 Strategy framework

Companies Mentioned

The major companies profiled in this Blood-based Biomarker for Alzheimer’s Disease Diagnostics market report include:
  • F. Hoffmann-La Roche Ltd
  • Quanterix
  • Fujirebio
  • C2N Diagnostics
  • Labcorp
  • Quest Diagnostics Incorporated
  • Siemens Healthineers
  • Lilly USA, LLC
  • Abbott
  • ALZpath

Related Topics

Related Reports

Middle East & Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report by Type (Amyloid-related Markers, Tau-related Markers), by Technology, by End-use, by Country, and Segment Forecasts, 2025-2033 - Product Image

Middle East & Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report by Type (Amyloid-related Markers, Tau-related Markers), by Technology, by End-use, by Country, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Africa, Middle East
From
U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis by Type (Amyloid-related Markers, Tau-related markers, Neurodegeneration), by Technology, by End Use, and Segment Forecasts, 2025-2033 - Product Image

U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis by Type (Amyloid-related Markers, Tau-related markers, Neurodegeneration), by Technology, by End Use, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • United States
From
U.S. Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report by Sample (Blood, Saliva), by Product (Reagents & Kits, Consumables), by Biomarker, by Diseases, by End Use, and Segment Forecasts, 2025-2033 - Product Image

U.S. Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report by Sample (Blood, Saliva), by Product (Reagents & Kits, Consumables), by Biomarker, by Diseases, by End Use, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • United States
From
U.S. Blood-based Biomarker For Parkinson's Disease Market Size, Share & Trends Analysis Report By Biomarker Type (Protein Biomarkers, Inflammatory Markers), By Technology (ELISA/Immunoassay, Multiplex Platforms), By End Use, And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Blood-based Biomarker For Parkinson's Disease Market Size, Share & Trends Analysis Report By Biomarker Type (Protein Biomarkers, Inflammatory Markers), By Technology (ELISA/Immunoassay, Multiplex Platforms), By End Use, And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • United States
From
Blood Tests for Alzheimer's Diagnosis Market - Global Forecast 2025-2030 - Product Image

Blood Tests for Alzheimer's Diagnosis Market - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.